Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
Williamson, D.S., Smith, G.P., Acheson-Dossang, P., Bedford, S.T., Chell, V., Chen, I.J., Daechsel, J.C.A., Daniels, Z., David, L., Dokurno, P., Hentzer, M., Herzig, M.C., Hubbard, R.E., Moore, J.D., Murray, J.B., Newland, S., Ray, S.C., Shaw, T., Surgenor, A.E., Terry, L., Thirstrup, K., Wang, Y., Christensen, K.V.(2017) J Med Chem 60: 8945-8962
- PubMed: 29023112 
- DOI: 10.1021/acs.jmedchem.7b01186
- Primary Citation of Related Structures:  
5OOP, 5OOR, 5OP2, 5OOT, 5OP5, 5OP4, 5OPS, 5OPR, 5OPU, 5OQ6 - PubMed Abstract: 
Mutations in leucine-rich repeat kinase 2 (LRRK2), such as G2019S, are associated with an increased risk of developing Parkinson's disease. Surrogates for the LRRK2 kinase domain based on checkpoint kinase 1 (CHK1) mutants were designed, expressed in ins ...